Diabetic Retinopathy Severity Scale (DRSS)

About

The Diabetic Retinopathy Severity Scale was developed by the Early Treatment Diabetic Retinopathy Study (ETDRS) and later simplified by the International Clinical Diabetic Retinopathy Disease Severity Scale (ICDR) as an international consensus standard. The scale classifies retinopathy into 5 levels based on findings on dilated fundus examination: Level 0 — No apparent retinopathy (NDR). Level 1 — Mild non-proliferative diabetic retinopathy (NPDR) characterized by microaneurysms only. Level 2 — Moderate NPDR with more than microaneurysms but less than severe NPDR, including dot-blot hemorrhages, hard exudates, and venous beading. Level 3 — Severe NPDR defined by the 4-2-1 rule: hemorrhages in all 4 quadrants, venous beading in ≥2 quadrants, or intraretinal microvascular abnormalities (IRMA) in ≥1 quadrant. Level 4 — Proliferative diabetic retinopathy (PDR) with neovascularization of the optic disc (NVD) or elsewhere (NVE), vitreous/preretinal hemorrhage, or tractional retinal detachment. The ETDRS also includes a separate classification for diabetic macular edema (DME): absent vs present (mild, moderate, severe). The DRSS is required reporting in all major diabetic retinopathy clinical trials and is the standard for clinical care.

Formula

DRSS Level = 0 (NDR), 1 (Mild NPDR), 2 (Moderate NPDR), 3 (Severe NPDR), 4 (PDR)

Level 0 (NDR): No retinal abnormalities visible on dilated fundus examination in a diabetic patient. Level 1 (Mild NPDR): At least one microaneurysm, and findings less than moderate NPDR. Microaneurysms appear as tiny red dots in the retinal layers. Level 2 (Moderate NPDR): More extensive intraretinal hemorrhages (dot-blot hemorrhages — red round or blot-shaped), hard exudates (yellow-white lipid deposits), cotton-wool spots (nerve fiber layer infarcts), or venous beading (irregular venous caliber), but less than severe NPDR. Level 3 (Severe NPDR): The 4-2-1 rule — (1) severe hemorrhages in all 4 quadrants of the retina (moderate to severe intraretinal hemorrhages in all quadrants), (2) venous beading in 2 or more quadrants, (3) IRMA (intraretinal microvascular abnormalities — abnormal small-caliber retinal vessels) in 1 or more quadrants. Level 4 (PDR): One or more of: neovascularization on the optic disc (NVD), neovascularization elsewhere (NVE) in the retina, vitreous hemorrhage (blood in the vitreous cavity), or tractional retinal detachment (retinal detachment caused by fibrovascular proliferation and contraction).

Score Interpretation

The DRSS is the foundation of diabetic retinopathy management worldwide. Diabetic retinopathy is the leading cause of preventable blindness in working-age adults, affecting approximately 103 million people globally. The scale's clinical significance spans multiple applications: (1) Screening interval determination — patients with NDR or mild NPDR need annual screening; moderate NPDR needs 6-12 month screening; severe NPDR needs 3-4 month intervals. (2) Treatment decisions — PDR requires prompt treatment with PRP or anti-VEGF therapy; severe NPDR may benefit from PRP in select cases (type 2 diabetes, pregnancy, poor follow-up). (3) Prognosis — the 4-year risk of developing PDR is 15-50% for severe NPDR compared to 5-15% for moderate NPDR. (4) Clinical trial endpoints — DRSS progression is the most common primary endpoint in diabetic retinopathy clinical trials, with DRSS worsening by ≥2 steps or progression to PDR as standard endpoints. The DRSS also correlates with visual outcomes; patients with PDR and DME have the highest risk of vision loss.

Reference Ranges